


# **PROJECTS IN 2025**



#### **OF GE Healthcare**

are invtesting €132M to expand their Cork facility, focused on manufacturing contrast media - diagnostic imaging agents crucial for CT scans and X-Rays. This new 3000m² addition at the Carrigtwohill site will accommodate an output increase of 25 million patient doses per year by the end of 2027.

## OB Eli Lilly

A €726 million facility expansion in Kinsale is now in production, meeting demands for its diabetes and obesity treatments.

€ 732m 🗰 2024

## 09 MSD

announced its fourth phase of investment in its state-ofthe-art Carlow facility since setting it up in 2008. The site serves as a filling site for launch and commerical supply of vaccines, biologics and small molecule drug products and was MSD's first vaccines operation outside of the US.

€ 450m 100 = 2025

#### 10 Dexcom

In 2023 Dexcom announced their plans to invest €300 million over the next five years to build a new manufacturing site in Co Galway. The investment has the potential to create 1000 highly-skilled jobs. Construction and recruitment is well under way. The facility is scheduled to commence production in

€ 300m | 1000 = 2026

## On Bristol Myers Squibb

are investing €370 million to construct a new manufacturing plant as its Cruiserath campus in Dublin. The new facility will be the company's first European biologics sterile drug product facility and it will be support the manufacturing of existing medicines in addition to supporting future drugs.

€ 370m i 350 iii 2026

#### **O2** Zoetis

recently finished the first phase of its site expansion, which began in 2021. In February 2024, they unveiled plans for a second phase. The phase 2 investment of €150 million i ongoing, and the project should be completed in 2025.

€ 150m ∮ 90 🛗 2025 (Phase 2)

#### 03 Abbott

has opened a new diabetes technology manufacturing plant in Kilkenny as part of a €440 million investment the company is making in two of its Irish facilities. More than 800 people will be employed at the plant which will be the biggest production centre worldwide for the group's Freestyle Libre sensors.

€ 440m † 800 mm 2025

#### 04 Pfizer

are invesiting more than €1.2 billion in its Grange Castle manufacturing site in Dublin. The investment will double the capacity for biological drug substance manufacturing and enable the production of various pharmaceutical products including oncology, rare disease, inflammation and immunology, and internal medicines.

€ 1.2bn | 450 | 2027

## **05** BioMarin

is investing €60 million to expand its site in Shanbally in Cork. The investment will see the addition of a new four-storey lab facility that will enable the company to increase production capacity for approved medicines and create room for future growth.

**€** 60m

## Eli Lilly

has announced a further €927 million investment at its facility at Raheen in Limerick, creating a further 150 jobs there. Lilly's latest investment will allow for increased production at the Limerick plant, which is the most ambitious manufacturing expansion in the company's history, and will bring the number of people employed at the Raheen site to 450 when it goes into production this summer.

€ 927m 150 mm 2027